ARTICLE | Company News
Biogen agrees to outcomes-based contract for MS portfolio
December 1, 2017 11:13 PM UTC
Biogen Inc. (NASDAQ:BIIB) signed an outcomes-based contract with PBM Prime Therapeutics LLC for Biogen's multiple sclerosis drugs under Prime's CareCentered Contract program. Prime Therapeutics VP of Pharmaceutical Trade Relations Susan Scheid told BioCentury the contract will cover Biogen's portfolio of MS drugs and measure members' "overall appropriate medication use."
Biogen has a value-based contracting pilot program in place, according to an SEC filing. Prime said this contract is Biogen's only pilot with a national payer. Biogen did not respond to inquiries regarding its other pilots...
BCIQ Company Profiles